Abstract
The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described.
MeSH terms
-
Anticholesteremic Agents / therapeutic use
-
Arteriosclerosis / prevention & control
-
Atorvastatin
-
Clinical Trials as Topic*
-
Coronary Disease / prevention & control*
-
Coronary Disease / therapy*
-
Diabetes Mellitus, Type 2 / complications*
-
Fenofibrate / therapeutic use
-
Heptanoic Acids / therapeutic use
-
Humans
-
Hyperlipidemias / therapy*
-
Hypolipidemic Agents / therapeutic use
-
Pyrroles / therapeutic use
-
Risk Factors
Substances
-
Anticholesteremic Agents
-
Heptanoic Acids
-
Hypolipidemic Agents
-
Pyrroles
-
Atorvastatin
-
Fenofibrate